Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hetrombopag - Jiangsu Hengrui Medicine Co.

Next Previous
Drug Profile

Hetrombopag - Jiangsu Hengrui Medicine Co.

Alternative Names: Hengqu; Herombopag olamine; Hetrombopag olamine; Hytrapopapa ethanolamine; Hytrapopapamin; SHR 8735; SHR 8735 olamine

Latest Information Update: 22 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Atridia; Jiangsu Hengrui Medicine Co.
  • Class Antianaemics; Antihaemorrhagics; Aza compounds; Carboxylic acids; Furans; Pyrazolones; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombocytopenia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura
  • Phase III Thrombocytopenia
  • No development reported Unspecified

Most Recent Events

  • 22 Dec 2025 Jiangsu HengRui Medicine plans a phase III trial for Thrombocytopenia (Chemotherapy induced) in February 2026 (NCT07286032)
  • 06 Dec 2025 Efficacy and adverse events data from a phase-III trial in Idiopathic thrombocytopenic purpura presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 06 Dec 2025 Adverse events and efficacy data from a phase III trial in Thrombocytopenia presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top